Wren Therapeutics has developed oral small molecules that suppress the production of toxic alpha-synuclein protein forms in cellular and mouse models used to study Parkinson’s disease. The potential first-in-class molecules were designed with Wren’s technology platform to hinder processes involved in the generation of alpha-synuclein oligomers, the…

Athira Pharma is completing its Phase 2 clinical trial of the experimental therapy fosgonimeton in people with Parkinson’s disease dementia or dementia with Lewy bodies with fewer participants than its initial target enrollment. According to a recent corporate update, the company has closed recruitment with 28 of…

People with REM sleep behavior disorder (RBD) — an early nonmotor symptom of Parkinson’s disease — were significantly more likely than others to wrongly think their sense of smell was normal when olfactory deficits were evident, a small study found. Parkinson’s patients with RBD also had a diminished sense…

Treatment with CST-103, CuraSen Therapeutics’ investigational oral molecule, safely led to cognitive improvements in people with Parkinson’s disease or mild cognitive impairment (MCI), according to top-line data from a Phase 2 clinical trial. By combining the CST-103, which is able to enter the brain, with a molecule…

SLS-004, Seelos Therapeutics‘ investigational gene therapy for Parkinson’s disease, lowered alpha-synuclein levels and prevented the degeneration of dopamine-producing, or dopaminergic, neurons in a mouse model of the disease, the company announced. A hallmark of the neurodegenerative disease, the loss of dopaminergic neurons in a brain region called the…

Levels of alpha-synuclein, beta-amyloid, and neurofilament light chain (NfL) in the cerebrospinal fluid (CSF) that surrounds the brain and the spinal cord can help identify Parkinson’s disease and distinguish it from atypical parkinsonism, according to a review study. The study, “A meta-analysis of the diagnostic…

An experimental vaccine that stimulates immune responses against three regions of the alpha-synuclein protein — whose toxic clumps contribute to Parkinson’s disease and dementia with Lewy bodies (DLB) — is moving into late-stage preclinical research aimed at supporting future requests to test it in clinical trials. Called PV-1950R,…

Changes in the structure of 76 proteins in the cerebrospinal fluid (CSF) of people with Parkinson’s disease were seen when compared with those of healthy individuals, a study reported. Its researchers believe their work is the first to look at protein structure — rather than abundance — to identify potential…

Early studies in nerve cells and a rat model of Parkinson’s disease support the potential of fosgonimeton, also known as ATH-1017, to be neuroprotective and possibly disease modifying, Athira Pharma, the therapy’s developer, reported. Data from preclinical work showed that the therapy increased cell survival in the…

NKGen Biotech is partnering with the Parkinson’s Foundation to help accelerate clinical research on its natural killer cell therapy, SNK01, for advanced Parkinson’s disease. “We are very impressed with the Parkinson’s Foundation’s holistic approach towards improving patient care and supporting cutting-edge research,” Paul Y. Song, MD, NKGen…